Table 1 Patient characteristics, treatment regimens and treatment responses
From: Excellent survival in relapsed stage I testicular cancer
Cohort A (n = 81) | Cohort B (n = 245) | |
|---|---|---|
Age at diagnosis (year), median (range) | 33 (16 – 66) | 34 (17 – 69) |
Histological subtype in primary tumor, number (%)a | ||
Pure seminoma | 41 (50.6%) | 72 (29.4%) |
Non-seminoma / mixed germ cell tumor | 40 (49.4%) | 161 (65.7%) |
Pure Teratoma | 0 | 10 (4.1%) |
Serum tumor markers prior to treatment, number (%)b | ||
AFP median (range) | 3.1 (n – 104) | 4.5 (n – 63951) |
< 1000 ng/ml | 71 (100%) | 210 (91.7%) |
> 1000 and < 10000 ng/ml | 0 | 14 (6.1%) |
> 10000 ng/ml | 0 | 5 (2.2%) |
Missing values | 10/81 (12.3%) | 16/245 (6.5%) |
HCG median (range) | 0 (n – 549) | 8 (n-1′995′937) |
< 5000 IU/l | 73 (100%) | 200 (86.6%) |
> 5000 and < 50′000 IU/l | 0 | 14 (6.1%) |
> 50′000 IU/l | 0 | 17 (7.4%) |
Missing values | 8/81 (9.9%) | 14/245 (5.7%) |
LDH median (range) | 360.5 (n – 1038) | 416 (n – 5666) |
< 1.5 × ULN | 40 (60.6%) | 73 (34.8%) |
> 1.5 × and < 10 × ULN | 26 (39.4%) | 129 (61.4%) |
> 10 × ULN | 0 | 8 (3.9%) |
Missing values | 15/81 (18.5%) | 35/245 (14.3%) |
IGCCCG risk classification, number (%)c | ||
Good prognosis | 70 (86.4%) | 135 (55.1%) |
Intermediate prognosis | 11 (13.6%)d | 73 (29.8%) |
Poor prognosis | 0 | 34 (13.9%) |
Treatment for metastatic disease | ||
BEP | 55 (67.9%) | 174 (71.0%) |
EP | 7 (8.6%) | 27 (11.0%) |
VIP / TIP | 3 (3.7%) | 17 (6.9%) |
Othere | 9 (11.1%) | 14 (5.7%) |
Surgery | 7 (8.6%) | 0 |
Missing data | 0 | 9 (3.7%) |
Residual tumor resection post chemotherapy | 12 (14.8%) | 82 (34.5%) |
Radiotherapy post chemotherapy | 10 (13.2%) | 13 (5.4%) |
Treatment response | ||
Complete response (CR) | 54 (68.4%) | 77 (33.2%) |
CR after residual tumor resection (CRar) | 13 (16.4%) | 59 (25.4%) |
Partial response (PR) | 11 (13.9%) | 90 (38.8%) |
Stable disease (SD) / Progressive disease (PD) | 0 | 6 (2.6%) |
Missing data | 1 (1.2%) | 13 (5.3%) |